Background: Glomerulopathy is an increasingly identified complication in young patients with sickle cell disease (SCD). Hyperfiltration and albuminuria followed by declining glomerular filtration rates and eventual end-stage renal disease (ESRD) is assumed to be the typical progression of glomerular disease. There are only a few reported biomarkers to identify early-stage renal disease in SCD.
INTRODUCTION
Sickle cell disease (SCD) is a monogenic disorder that affects millions of people worldwide. Renal disease, including glomerulopathy, is a prevalent complication among adult patients and is a prominent Abbreviations: ACE, angiotensin converting enzyme; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HbAA, hemoglobin AA; HbSS, hemoglobin SS; IQR, interquartile range; NCR, nephrin-creatinine ratio; NPV, negative predictive value; PPV, positive predictive value; ROC, receiver operating characteristic; SCD, sickle cell disease; sFLT-1, soluble fms-like tyrosine kinase-1; UACR, urine albumin-creatinine ratio; UNC, disease. However, the surveillance of sickle glomerulopathy is limited by a dearth of clinically validated biomarkers. Current guidelines and best practices recommend the use of routine urinalysis as well as evaluation of microalbuminuria in the surveillance of renal disease. However, this strategy only identifies patients with clinically evident renal disease. A previous study of renal disease in patients with SCD found that the presence of measurable albuminuria is accompanied by a loss of glomerular permselectivity despite normal glomerular filtration rate (GFR), and suggests the presence of irreversible damage. 8 Early detection of renal disease with use of novel biomarkers could enable earlier intervention and subsequent slowing of disease progression, potentially limiting irreversible damage to the kidney.
The current treatment strategy of albuminuria is similar to that of other proteinuric renal diseases with the mainstay approach involving the use of angiotensin converting enzyme (ACE) inhibitors, and more recently angiotensin receptor blockers. There are no published studies of any long-term therapies for proteinuria in SCD.
However, short-term treatment with ACE inhibitors significantly decreases both microalbuminuria and macroalbuminuria. [9] [10] [11] Hydroxyurea, approved by the US Food and Drug Administration to treat sickle cell anemia, may have renoprotective effects. Specifically, treatment of adult patients with hydroxyurea is associated with lower levels of albuminuria. 12 Treatment of children with hydroxyurea also resulted in decreased glomerular hyperfiltration and glomerular hypertrophy. 12 A recent prospective, open-label study reported improvement in albuminuria following 6 months of treatment with hydroxyurea. 13 Nephrin is a slit diaphragm protein that is critical for glomerular filtration as it provides architectural support to podocytes. Nephrin shedding is used as a marker of glomerular-specific renal damage in a variety of settings and was observed prior to the development of albuminuria in a mouse model of proteinuric renal disease. 14 Increased levels of urinary nephrin are present in humanized sickle cell mice and correlate with estimated glomerular filtration rate (eGFR) in adults with SCD. 15, 16 As nephrinuria develops before albuminuria, nephrin may be a suitable biomarker for early detection of glomerulopathy in SCD.
We have recently introduced hemoglobin electrophoresis testing and clinically characterized a cohort of children in Lilongwe, Malawi. 17 Malawi is a country of 18 million people in Southeastern Africa and has a substantial SCD burden, but only scarce resources for its diagnosis and treatment. 18, 19 In this study, we describe the renal profile of children with SCD followed at Kamuzu Central Hospital, a tertiary referral hospital, in Lilongwe, Malawi. We propose that nephrin, an early marker of glomerular injury, is associated with albuminuria and may represent a potential novel urinary biomarker for the identification of children with early renal disease.
METHODS
Consecutive patients seen at a pediatric chronic care clinic at Kamuzu Central Hospital in Lilongwe, Malawi, between January and May 2015 were recruited. The University of North Carolina at Chapel Hill (UNC) Institutional Review Board and Malawi National Health Science Review Committee approved the study. Written informed consent was obtained from the parents of 119 enrolled children. One patient declined participation in the study. Children aged 7-17 years also provided informed assent prior to study participation.
Laboratory analyses
Routine laboratory studies, including complete blood counts, chemistries, hemoglobin electrophoresis, and urinalysis were performed by the UNC Project laboratory in Lilongwe, Malawi. The normal ranges for clinical laboratory variables are provided in Supplementary   Table S1 . Plasma and urine samples were aliquoted and frozen immedi- (the median value in the cohort) was performed and the odds ratio for albuminuria with urine NCR above and below 622 ng/mg was estimated. Finally, Spearman correlation coefficients evaluating the associations of urine NCR with other laboratory variables were calculated.
Reported P-values are for individual tests, unadjusted for multiple comparisons because of the exploratory nature of this study. The ROC curve for urinary NCR was generated using R (version 3.3.2), and other analyses were conducted using SAS University Edition (SAS Institute, Cary, NC).
RESULTS
One hundred and nineteen children were evaluated, with 101 con- Table S1 ). Median urinary NCR was also higher in HbSS patients compared with individuals with HbAA. Albuminuria, defined as UACR of 30 mg/g or higher, was present in 24.8% of HbSS patients.
The median UACR in the albuminuria subgroup of HbSS patients was 58.8 mg/g (IQR: 52.7-125.4) versus 0.0 mg/g (IQR: 0.0-9.9) in patients without albuminuria. In univariate analyses, patients with higher urinary NCR had significantly higher odds of albuminuria (P = 0.0003).
However, no other significant associations were seen between laboratory variables and albuminuria (Table 2 ).
In the multivariable logistic regression analysis, only urinary NCR was significantly associated with albuminuria (odds ratio estimate = 1.002, 95% confidence interval [CI] {1.001, 1.003}, P = 0.0003).
Additional analysis using an NCR cut-point of 622 ng/mg, the median value for the cohort, revealed a 45.9 times greater odds of having albuminuria in children with NCR above this value. The area under the ROC curve that illustrates the ability of urinary NCR in predicting and an NPV of 80% for the presence of albuminuria.
TA B L E 3 Spearman correlation coefficients of laboratory variables with urinary nephrin-creatinine ratio
Urinary NCR was positively correlated with total and indirect bilirubin levels while negatively correlated with D-dimer levels (P < 0.05).
However, no significant correlations were seen between urinary NCR and hemoglobin or serum creatinine (Table 3 ). In addition, a significant correlation was not observed between NCR and eGFR (r = 0.03, P = 0.84).
DISCUSSION
Albuminuria is a common complication in SCD, with an increasing recognition of its high prevalence in young patients. 3 other apparent cause, be started on ACE inhibitor therapy, the natural history of albuminuria in patients with sickle cell anemia remains inadequately defined. 23 However, multiple studies suggest that kidney function declines over time in patients with SCD. [24] [25] [26] Indeed,
we have recently reported a rate of decline in eGFR of 2.15 ml/min per 1.73 m 2 per year, much greater than that expected for healthy individuals. 27, 28 The high prevalence of albuminuria in our patient cohort in Malawi suggests early, severe glomerular disease in young patients with SCD.
This is similar to the results from a large, multicenter study in West
Africa that reported a prevalence of 27% in children who were less than 10 years old. 29 A recent study of patients from Cameroon reported a prevalence of albuminuria of 60%, although this cohort was older than our patient cohort, with an average patient age of 15 years. 30 In the multivariable logistic regression analysis, only NCR was significantly associated with albuminuria. Urinary nephrin has been reported to correlate with urine albumin concentration in a small cohort of adult patients with SCD. 16 However, our study is the first to report the association of NCR with albuminuria in young children with SCD. Although the specificity and PPV of NCR (with a cut-point at the 50 th percentile) for albuminuria in our study are modest, the sensitivity and NPV are high. As nephrin is a glomerular-specific protein, monitoring of this biomarker might be more indicative of glomerular injury than other putative biomarkers in the current literature. 31 Furthermore, evaluation of a urine biomarker is more convenient in a pediatric population than a plasma-based biomarker. With its high sensitivity and NPV, nephrin represents a plausible and easily accessible biomarker for the early diagnosis of glomerulopathy associated with SCD.
In our patient cohort, D-dimer was negatively correlated with NCR.
In addition, we observed that D-dimer appeared to be inversely associated with albuminuria, although this was not statistically significant.
D-dimer is an assayable product of fibrin degradation that is elevated in the plasma during clotting and thrombosis. There is increasing evidence that SCD is a hypercoagulable state. 32 In addition to an increased risk of thrombotic complications, patients with SCD have evidence of coagulation activation, with increased levels of markers of thrombin generation, even in the noncrisis "steady states." High concentrations of thrombin may contribute to podocyte injury. 33 It is suggested that thrombin may contribute to progression of proteinuria in animal models of nephrotic syndrome. 34 The role of coagulation activation in SCD pathophysiology is highlighted by a recent study which showed that genetic reduction in prothrombin levels in sickle mice not only resulted in decreased levels of thrombin-antithrombin complexes and D-dimer, but also produced significant reductions in renal complications, including albuminuria, compared with wild type sickle mice. 35 In light of these previous reports, the negative association between D-dimer and both NCR and UACR was surprising and unexpected.
Additional studies in patients with SCD are required to clarify the relationship between coagulation activation and glomerulopathy. ally, despite the reported role for hyperfiltration in the pathogenesis of albuminuria in SCD, 44, 45 we found no association between the presence of albuminuria and eGFR in this study. Furthermore, we did not observe any association between albuminuria and either VEGF or VEGFR-1.
Our study has several limitations. All the study patients were recruited from a tertiary hospital clinic in Malawi. As with other populations in sub-Saharan Africa, the highest mortality is thought to occur in the less than 5-year age group. 46 As such, there is a possible survivor bias in our population resulting in an overall healthier cohort than might otherwise exist. The gold standard for measurement of albuminuria is a 24-hour urine collection. However, 24-hour collections are particularly tedious in the setting of a developing country such as Malawi. Furthermore, we have previously reported very strong correlations between spot assessments for UACR and 24-hour urine protein collections, providing support for the use of spot urine collections to evaluate albuminuria in patients with SCD. 47 As with all crosssectional studies, this analysis demonstrates associations, but cannot prove causation.
CONCLUSION
These data taken together suggest that a substantial proportion of children with SCD in Malawi exhibit renal involvement early in life and could be at risk for worsening glomerulopathy and ESRD as they grow older. Our data further indicate that urinary nephrin is asso- 
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